CANOMAD unmasked by COVID‐19 in a man with Waldenström's macroglobulinaemia
Open Access
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell–targeted therapiesBlood, 2020
- Guillain-Barré syndrome: The first documented COVID-19–triggered autoimmune neurologic diseaseNeurology Neuroimmunology & Neuroinflammation, 2020
- Miller Fisher syndrome and polyneuritis cranialis in COVID-19Neurology, 2020
- Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?The Lancet Neurology, 2020
- Peripheral nervous system involvement in lymphomasJournal of the Peripheral Nervous System, 2018
- Investigation and management of IgM and Waldenström‐associated peripheral neuropathies: recommendations from the IWWM‐8 consensus panelBritish Journal of Haematology, 2017
- Successful treatment of CANOMAD with IVIg and rituximabJournal of Neurology, 2013
- Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studiesActa Neurologica Scandinavica, 2009
- The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodiesBrain, 2001
- Monoclonal IgM in a patient with paraproteinemic polyneuropathy binds to gangliosides containing disialosyl groupsAnnals of Neurology, 1985